People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to Wegovy across the trial. The detailed results were presented at the 32 nd ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

(Shipping Not Included) Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia) (Jonel Aleccia) People taking ...